Table 2.
Clinical features of patients with myelodysplastic syndromes
| Clinical feature | IPSS Low; Int-1 (n = 24) | IPSS Int-2; High (n = 11) | Stable MDS | Developed AML | Total |
|---|---|---|---|---|---|
| No. of patients | 12; 12 | 7; 4 | 23 | 12 | 35 |
| Median age, y (range) | 68 (45-88) | 72 (57-81) | 71 (51-88) | 67 (45-77) | 69 (45-88) |
| FAB | |||||
| RA; RARS | 21; 2 | 0; 0 | 18; 2 | 3; 0 | 21; 2 |
| RAEB-1 | 1 | 2 | 2 | 1 | 3 |
| RAEB-2; RAEBT | 0 | 3; 6 | 1; 0 | 2; 6 | 3; 6 |
| Cytogenetics | |||||
| Normal | 8 | 4 | 9 | 3 | 12 |
| del(5q) | 9 | 1 | 8 | 2 | 10 |
| Abnormal, non-del(5q) | 7 | 6 | 6 | 7 | 13 |
| Median survival, mo (range) | 45 (12-102) | 11 (2-27) | 46 (5-102) | 12 (2-27) | 35 (2-102) |
| AML evolution | |||||
| Yes | 3 | 9 | 0 | 12 | 12 |
| No | 21 | 2 | 23 | 0 | 23 |
| IPSS Low; Int-1 | 12; 12 | 0 | 12; 9 | 0; 3 | 12; 12 |
| IPSS Int-2; High | 0 | 7; 4 | 2; 0 | 5; 4 | 7; 4 |
Median follow-up was 4.3 years (range, 0.2-8.5 years).